Prices delayed by at least 15 minutes | Print
Hikma Pharmaceuticals PLC (HIK)
ORD SHS 10PThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Regular investment and Dividend reinvestment
Company profile
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Address
1 New Burlington Place
London
GBR
W1S 2HR
Telephone
+44 2073992760
Forecast key dates
| Name | Key Date |
|---|---|
| Hikma Pharmaceuticals PLC Annual General Meeting for 2025 | 2026-04-24T11:30:00 |
| Hikma Pharmaceuticals PLC Annual Report for 2025 | 2026-03-13T00:00:00 |
| Hikma Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2025 | 2026-02-26T09:00:00 |
| Hikma Pharmaceuticals PLC Fourth Quarter Earnings Results for 2025 | 2026-02-26T00:00:00 |
| Hikma Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2025 | 2025-08-08T00:00:00 |
| Hikma Pharmaceuticals PLC Second Quarter Earnings Results for 2025 | 2025-08-07T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Hikma Pharmaceuticals PLC Annual General Meeting for 2024 | 2025-04-24T11:30:00 |
| Hikma Pharmaceuticals PLC Annual Report for 2024 | 2025-03-14T00:00:00 |
| Hikma Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2024 | 2025-02-26T09:00:00 |
| Hikma Pharmaceuticals PLC Fourth Quarter Earnings Result for 2024 | 2025-02-26T00:00:00 |
| Hikma Pharmaceuticals PLC Second Quarter Earnings Results for 2024 | 2024-08-08T00:00:00 |
| Hikma Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2024 | 2024-08-08T00:00:00 |
| Deutsche Numis Q&A with CEO | 2024-06-03T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.